Adalimumab-ryvk Kit
Product Images NDC 82009-158

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Adalimumab-ryvk (NDC 82009-158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F1 (Avt02 Pld Q 1)

A line graph showing the percentage of ACR20 responders over time in weeks, comparing the response between a 40 mg every other week dosing group and a placebo group. The graph indicates higher response rates in the 40 mg group across the observed period.*

FDA Label Image

6 (Avt02 Pld Q 10)

An instructional illustration labeled "Figure E" showing a person rinsing their hands under running water, with water and soap bubbles visible. This suggests a step in hand hygiene preparation.*

FDA Label Image

7 (Avt02 Pld Q 11)

An illustration showing a front view of a human torso with highlighted injection sites for subcutaneous administration. Areas marked in orange include the abdomen around the navel and the front of both thighs. This diagram is related to the subcutaneous route of administration for Adalimumab-ryvk kit.*

FDA Label Image

8 (Avt02 Pld Q 12)

An instructional illustration labeled Figure G showing a hand wiping a circular area on the skin with a cotton pad or swab, accompanied by circular arrows indicating a circular motion likely for cleansing the injection site.*

FDA Label Image

9 (Avt02 Pld Q 13)

An instructional illustration showing the Adalimumab-ryvk injection pen with a close-up inset highlighting the window indicator on the device. The image includes label text of the product name and strength: 40 mg/0.4 mL, and the Quallent Pharmaceuticals logo is visible.*

FDA Label Image

10 (Avt02 Pld Q 14)

An illustrated instructional diagram showing a hand holding an Adalimumab-ryvk subcutaneous kit component, with a focus on applying or positioning a small square adhesive patch or pad below it. This figure is labeled as Figure I and appears to demonstrate a step in the preparation or administration process using the kit.*

FDA Label Image

11 (Avt02 Pld Q 15)

An instructional illustration showing a hand holding an Adalimumab-ryvk injection device at a 90-degree angle to the skin on another hand, demonstrating proper subcutaneous injection technique for the Adalimumab-ryvk 0.7 mL/mL kit by Quallent Pharmaceuticals Health LLC.*

FDA Label Image

12 (Avt02 Pld Q 16)

Illustration showing the use of an Adalimumab-ryvk subcutaneous injection kit. It depicts a hand pressing the injection device onto the skin with the labeler logo visible. It highlights a two-step clicking mechanism: the first click with a corresponding color change in the window, a wait time of up to 10 seconds, then the second click with a further color change.*

FDA Label Image

13 (Avt02 Pld Q 17)

Illustration showing the use of Adalimumab-ryvk 0.7 mL subcutaneous injection kit. The top image depicts a hand holding a prefilled syringe or pen with an arrow indicating upward motion. The bottom image shows a hand pinching skin, likely demonstrating preparation of the injection site prior to administration.*

FDA Label Image

14 (Avt02 Pld Q 18)

An instructional illustration showing a human hand disposing of an Adalimumab-ryvk prefilled syringe into a red biohazard sharps container. The syringe is white with an orange needle cover being inserted into the container's yellow-lidded circular opening, demonstrating proper syringe disposal.*

FDA Label Image

15 (Avt02 Pld Q 19)

FDA Label Image

F2 (Avt02 Pld Q 2)

A line graph showing the percentage of ASAS 20 response over 24 weeks comparing Adalimumab-ryvk (solid line) versus placebo (dashed line). The y-axis represents percentage response, reaching up to 70%, and the x-axis represents time in weeks from 0 to 24. The graph illustrates that Adalimumab-ryvk achieves a higher response rate than placebo throughout the time period.*

FDA Label Image

16 (Avt02 Pld Q 20)

Packaging label for Adalimumab-ryvk Injection 40 mg/0.4 mL kit by Quallent Pharmaceuticals Health LLC. The label indicates the product is for subcutaneous use only and contains 2 single-dose autoinjectors. The label also features a color image of the autoinjector and includes branding and regulatory information.*

FDA Label Image

Fig3 (Avt02 Pld Q 3)

A line graph comparing treatment failure rates over 20 months between a placebo group and an Adalimumab group. The vertical axis represents treatment failure rate percentage, and the horizontal axis denotes time in months. The graph shows lower treatment failure in the Adalimumab group compared to placebo over the study duration.*

FDA Label Image

F3a (Avt02 Pld Q 4)

A line graph comparing treatment failure rates over 20 months for Adalimumab and placebo groups. The X-axis represents time in months and the Y-axis shows treatment failure percentage. Lines depict an increasing failure rate over time with distinct curves for placebo and Adalimumab treatments.*

FDA Label Image

1 (Avt02 Pld Q 5)

Illustration diagram of an Adalimumab-ryvk 40 mg/0.4 mL subcutaneous injection kit showing labeled parts: clear cap covering the needle, orange needle sleeve, inspection window, and gray body grip area with a honeycomb pattern. The label includes storage instructions and the Quallent logo.*

FDA Label Image

2 (Avt02 Pld Q 6)

An instructional diagram labeled Figure A showing a hand inserting a rectangular object, possibly a drug delivery device or component, into a machine or compartment with an arrow indicating the direction of insertion.*

FDA Label Image

3 (Avt02 Pld Q 7)

Illustration of a clock showing a time interval from 15 to 30 minutes highlighted in red on the right half. The text "15 to 30 minutes" is centered on the clock face, with black hour marks at the 12, 3, 6, and 9 positions. Captioned as Figure B.*

FDA Label Image

4 (Avt02 Pld Q 8)

An instructional diagram labeled Figure C showing a subcutaneous injection kit for Adalimumab-ryvk, including parts of a syringe and a cartridge. The diagram highlights where to find the expiration date and lot number on the device, indicated as EXP: YYYY/MM/DD and LOT no., with a note to keep refrigerated. The components include a white and orange assembly and a black part with text and textured grip.*

FDA Label Image

5 (Avt02 Pld Q 9)

An instructional diagram labeled Figure D featuring components of a subcutaneous injection kit for Adalimumab-ryvk. The image includes a prefilled syringe labeled with drug information, an alcohol swab packet, a cotton ball, and a red sharps disposal container with a yellow lid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.